A Pilot Open-Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 13 Apr 2018
At a glance
- Drugs GSK 3377794 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Adaptimmune
- 09 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.